Investigating new treatments for HIV, TB, and hepatitis B.
Official title: Analysis of Chemical Structures and Therapeutic Activity of Agents for HIV, TB, and HBV (CHEMDB)
Funded at Gryphon Scientific, LLC · NIH-11167409 · Data updated 2026-11-12
This study is looking at different chemicals to find new treatments for HIV, tuberculosis, and hepatitis B, so that patients can have better options to fight these infections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Gryphon Scientific, LLC NIH-funded |
| Lab location | 1 site (Takoma Park, United States) |
| Project start | September 30, 2024 |
| Project end | September 29, 2025 |
| Funding year | 2024 |
| Award (this year) | $799,353 |
| NIH project number | 75N93020C00031-P00006-9999-1 |
| Project ID | NIH-11167409 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with HIV, TB, or hepatitis B virus.
✕Less likely to help
Patients with conditions unrelated to HIV, TB, or HBV may not receive any benefit from this research.
What this research studies
This research focuses on analyzing chemical structures and their therapeutic activities to identify potential treatments for HIV, tuberculosis (TB), and hepatitis B virus (HBV). By surveying chemical and biological information, the project aims to develop analytical tools that will aid in the rational selection of effective therapies. Patients may benefit from new treatment options that could emerge from this research, which seeks to enhance the understanding of how different compounds can combat these serious infections.
Why it matters
Potential benefit: If successful, this research could lead to the development of new and more effective therapies for patients suffering from HIV, TB, and HBV.
How similar studies have gone: Previous research has shown success in identifying therapeutic compounds for similar viral infections, indicating that this approach has potential.
Where this research is happening
-
Gryphon Scientific, LLC
Takoma Park, United States Active
Researchers
- Principal investigator: Sumner, Louise — Gryphon Scientific, LLC
- Study coordinator: Sumner, Louise
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.